TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1498372
Drug: Topical khellin
Normalized name: khellin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical khellin (2% solution in acetone and propylene glycol) plus sunlight exposure for 4 months with 3 weekly applications and exposure times up to 90 min.
Study: 1498372
Drug: Placebo (acetone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (acetone and propylene glycol) plus sunlight exposure for 4 months with 3 weekly applications and exposure times up to 90 min.
Study: 710312
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin (3 X 5000 IU/24 h)
Study: 902597
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (3.6 g daily)
Study: 30324251
Drug: Drug-induced movement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-induced movement disorders
Study: 21844490
Drug: Telemonitoring and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemonitoring and study physician medication management
Study: 9635648
Drug: Protocol group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol group (DO2 > or =600 mL/min/m2)
Study: 3341317
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate (975 mg/d)
Study: 21798642
Drug: USB-PRP combination
Normalized name: HEMOPHILUS B PRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: USB-PRP combination
Study: 16959690
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no additional hemostatic treatment)
Study: 3139428
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg sublingual nitroglycerin (Nitromex)
Study: 3139428
Drug: 0.50 mg
Normalized name: EVEROLIMUS 0.50 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 mg sublingual nitroglycerin (Nitromex)
Study: 3139428
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg sublingual nitroglycerin (Nitromex)
Study: 3139428
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg sublingual nitroglycerin (Nitromex)
Study: 3139428
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg ordinary nitroglycerin
Study: 31387119
Drug: Low fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fish oil (LFO) group (20% LC n‐3 PUFAs, 0.5 g/d)
Study: 31387119
Drug: High fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fish oil (HFO) group (60% LC n‐3 PUFAs, 2.0 g/d)
Study: 31387119
Drug: Control (CON)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (CON) group (0% LC n‐3 PUFAs, 0 g/d)
Study: 27225617
Drug: Oral dose
Normalized name: Exactamed Oral Dose Syringe 35cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of 50,000 IU vitamin D3 every week for 8 weeks, followed by 1 pearl every 2 weeks for 4 weeks (total of 3 months)
Study: 27225617
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no vitamin D treatment)
Study: 25438724
Drug: Encenicline 1
Normalized name: Encenicline
DrugBank: Encenicline (DB11726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encenicline 1 mg oral capsule
Study: 25438724
Drug: Encenicline 1
Normalized name: Encenicline
DrugBank: Encenicline (DB11726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encenicline 1 mg oral solution
Study: 25438724
Drug: Encenicline 20
Normalized name: Encenicline
DrugBank: Encenicline (DB11726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encenicline 20 mg dose
Study: 25438724
Drug: Encenicline 1-180
Normalized name: Encenicline
DrugBank: Encenicline (DB11726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encenicline 1-180 mg doses
Study: 25438724
Drug: Encenicline (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encenicline (various doses)
Study: 25438724
Drug: Encenicline (1-180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encenicline (1-180 mg)
Study: 21704313
Drug: Percutaneous E(2)
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous E(2) (100 μg/24 h) during 2 weeks perimenstrually
Study: 15112179
Drug: Doxercalciferol treatment
Normalized name: Doxercalciferol
DrugBank: Doxercalciferol (DB06410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxercalciferol treatment
Study: 15112179
Drug: Doxercalciferol treatment
Normalized name: Doxercalciferol
DrugBank: Doxercalciferol (DB06410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxercalciferol treatment and Placebo
Study: 10778998
Drug: Antiplatelet treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet treatment with ticlopidine (Group B)
Study: 10778998
Drug: Anticoagulant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant treatment with acenocoumarol (Group A)
Study: 9323513
Drug: L-Dopa treatment
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-Dopa treatment (ON)
Study: 9323513
Drug: OFF L-Dopa
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OFF L-Dopa
Study: 31080168
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept 2 mg every 8 weeks for 52 weeks, after 5 initial doses every 4 weeks.
Study: 30103252
Drug: Subcutaneous dalteparin
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous dalteparin
Study: 30284557
Drug: Subcutaneous dalteparin
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous dalteparin (in Select-D study)
Study: 23807272
Drug: MRKAd5 HIV‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRKAd5 HIV‐1 gag/pol/nef vaccine
Study: 23807272
Drug: Baseline risk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline risk behaviors (crack cocaine use, unprotected anal sex, drug use)
Study: 22112610
Drug: C421A variant
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: C421A variant (CA+AA versus CC) in ABCG2
Study: 17480139
Drug: Quyu Xiaoban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quyu Xiaoban capsules (QYXB) plus aspirin (300 mg loading dose, 100 mg maintenance dose) for 4 weeks
Study: 17480139
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg loading dose, 100 mg maintenance dose) for 4 weeks
Study: 15228130
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide 5%/clindamycin 1% gel (BP/C)
Study: 11754710
Drug: Rofecoxib, 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib, 12.5 mg/d
Study: 11754710
Drug: Celecoxib, 200
Normalized name: Celecoxib, 200 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib, 200 mg/d
Study: 11754710
Drug: Acetaminophen, 4000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen, 4000 mg/d
Study: 6658629
Drug: Cefoxitin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (2 g intramuscularly)
Study: 6658629
Drug: Penicillin (4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin (4.8 X 10(6) units aqueous procaine penicillin G intramuscularly)
Study: 15910834
Drug: Chloramphenicol ointment
Normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloramphenicol ointment applied at the surgical site at the end of procedure and 3rd day postoperatively
Study: 15910834
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no chloramphenicol ointment)
Study: 7977145
Drug: Milk chocolate
Normalized name: Meritene Milk Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk chocolate (280 g/d or 10 oz/d)
Study: 7977145
Drug: Milk chocolate
Normalized name: Meritene Milk Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk chocolate (46.2 g or 1.65 oz)
Study: 165862
Drug: Neutral red
Normalized name: neutral red
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral red photodynamic inactivation treatment
Study: 23680854
Drug: Manual-guided psychodynamic
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual-guided psychodynamic therapy
Study: 20113526
Drug: Snoezelen therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Snoezelen therapy
Study: 20113526
Drug: Structured reminiscence
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured reminiscence therapy
Study: 16614415
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g sesame seed powder daily for 5 weeks
Study: 11129729
Drug: Paclitaxel (Taxol)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (Taxol) at escalating doses starting from 100 mg/m2 up to 250 mg/m2; Cremophor EL starting dose of 8.3 ml/m2 with increments of 2.1 ml/m2; Carboplatin dosages of 300, 350, or 400 mg/m2.
Study: 8793497
Drug: GnRH analogue
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH analogue (goserelin) + oral contraceptive (OC) containing ethinyl estradiol and cyproterone acetate
Study: 8793497
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (OC) containing ethinyl estradiol and cyproterone acetate
Study: 1546145
Drug: moclobemide 150-150-150
Normalized name: moclobemide 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: moclobemide 150-150-150 mg
Study: 1546145
Drug: toloxatone 400-200-400
Normalized name: toloxatone
DrugBank: Toloxatone (DB09245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: toloxatone 400-200-400 mg
Study: 2689470
Drug: Meptazinol 50
Normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol 50 mg
Study: 6615689
Drug: Meptazinol 200
Normalized name: meptazinol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol 200 mg
Study: 3987183
Drug: Morphine 16
Normalized name: morphine sulfate 16 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 16 mg
Study: 27792719
Drug: Maggot debridement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maggot debridement therapy (MDT)
Study: 20676860
Drug: Topical lanolin
Normalized name: lanolin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lanolin ointment (PureLan)
Study: 20676860
Drug: Bovine type
Normalized name: Bovine type I collagen
DrugBank: Bovine type I collagen (DB10771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine type I collagen spray (Gelfix)
Study: 24691853
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no topical treatment)
Study: 18565251
Drug: Intra-articular hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular hyaluronic acid (HA) injections (3 injections with one-week interval)
Study: 18565251
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (6 weeks)
Study: 12236885
Drug: 3% 2-dimethylaminoethanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% 2-dimethylaminoethanol (DMAE) gel
Study: 12236885
Drug: Control formulation
Normalized name: nut.tx, weight loss-control formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control formulation without DMAE
Study: 7536438
Drug: Intradermal recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal recombinant human TNF-alpha (rHuTNF-alpha) 100 U (group A)
Study: 7536438
Drug: Intradermal recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal recombinant human TNF-alpha (rHuTNF-alpha) 5000 U (group B)
Study: 7536438
Drug: Intradermal recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal recombinant human TNF-alpha (rHuTNF-alpha) 100 U daily for 5 days (group C)
Study: 7536438
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (100 U and 5000 U, single injections; 100 U, multiple injections)
Study: 1665184
Drug: Lisinopril-hydrochlorothiazide (L/HCTZ)
Normalized name: fosinopril / hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril-hydrochlorothiazide (L/HCTZ) 20 mg/12.5 mg
Study: 6752873
Drug: Pirprofen (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirprofen (1000 mg/day)
Study: 6752873
Drug: Indomethacin (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (125 mg/day)
Study: 27023596
Drug: Elderberry extract
Normalized name: elderberry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elderberry extract (Sambucus nigra L.)
Study: 23521140
Drug: Chloroprocaine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroprocaine 40 mg (20 mg/ml)
Study: 21039353
Drug: Articaine 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Articaine 60 mg (40 mg/ml)
Study: 17392739
Drug: 17.5 mg
Normalized name: acitretin 17.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17.5 mg hydrocortisone (cortisol)
Study: 14760661
Drug: 800 ml
Normalized name: ALCOHOL 2660 mL in 3800 mL TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 ml of an iso-osmolar 12.5 percent carbohydrate-rich beverage (100 g carbohydrate) the evening before operation and another 400 ml (50 g carbohydrate) 2 hours before anaesthesia.
Study: 11918251
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release metoprolol 95 mg
Study: 9439530
Drug: Copper supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copper supplementation (2 mg/d for 4 weeks)
Study: 7513853
Drug: Simple sequential
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple sequential method
Study: 3428132
Drug: Ceftriaxone 100
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 100 mg/kg (max 4 g) intravenously (i.v.) once daily
Study: 3428132
Drug: Ampicillin i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin i.v. 160 mg/kg/day plus chloramphenicol i.v. 100 mg/kg/day every 6 h
Study: 28157671
Drug: Wheat germ-enriched
Normalized name: WHEAT GERM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat germ-enriched bread (6 g of wheat germ)
Study: 26024551
Drug: 6.4% carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.4% carbohydrate solution (CHO)
Study: 26024551
Drug: 6.4% carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.4% carbohydrate and 4 mg/kg caffeine (C+C)
Study: 23919853
Drug: Foley catheter
Normalized name: Bard Foley Catheter 18FR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foley catheter and synchronous low dose intravaginal misoprostol
Study: 23919853
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose intravaginal misoprostol alone
Study: 21097434
Drug: Cerebral State
Normalized name: Sus scrofa cerebral cortex preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebral State Index (CSI) during target controlled infusion (TCI) of propofol
Study: 10719590
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (Zinnat, 2 x 250 mg/d)
Study: 1313467
Drug: Oat bran
Normalized name: Oat bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat bran diet (123 g oat bran for 4 weeks)
Study: 1313467
Drug: Wheat bran
Normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat bran diet (54 g wheat bran for 4 weeks)
Study: 28877566
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no ginger capsules)
Study: 25185858
Drug: Activated protein
Normalized name: Activated protein C
DrugBank: Drotrecogin alfa (DB00055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated protein C (APC) with Topical Negative Pressure (TNP)
Study: 25185858
Drug: Topical Negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Negative Pressure (TNP) alone
Study: 22209257
Drug: Rhinomanometry after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhinomanometry after nasal decongestant (ND) xylometazoline
Study: 11249979
Drug: Azithromycin (31
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (31 patients) at a dose of 10 mg/kg once a week for 3 months
Study: 11249979
Drug: Amoxicillin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (40 patients) at a dose of 20 mg/kg per day for 3 months
Study: 7851352
Drug: naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen sodium 1100 mg 1 h prior to surgery
Study: 7851352
Drug: naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen sodium 1100 mg immediately after surgery
Study: 2755866
Drug: Topical 70%
Normalized name: ethanol topical 70% topical foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 70% dimethyl sulfoxide (DMSO)
Study: 2755866
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% dimethyl sulfoxide (DMSO)
Study: 341247
Drug: BCG immunotherapy
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG immunotherapy (75 mg of living BCG on a scratched area once a week)
Study: 30665152
Drug: Relay model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relay model (Danish screening brief intervention and referral to treatment)
Study: 16176400
Drug: Active SLIT
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active SLIT for 1 year, followed by 2 years of active treatment
Study: 30720541
Drug: Topical ripasudil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ripasudil 0.4% (Glanatec) 4 times a day for 2 months
Study: 30720541
Drug: Topical ripasudil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ripasudil 0.4% (Glanatec)
Study: 27528215
Drug: Education based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education based on phosphorus‐reducing techniques in food preparation and two hospital meals prepared using suggested cooking methods
Study: 26442397
Drug: Neostigmine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine group (group N) received bupivacaine 20 mg combined with 25 µg neostigmine.
Study: 26442397
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (group C) received bupivacaine 20 mg combined with 0.5ml distilled water.
Study: 14681344
Drug: YH1885 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH1885 60 mg single dose
Study: 14681344
Drug: YH1885 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH1885 100 mg single dose
Study: 14681344
Drug: YH1885 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH1885 150 mg single dose
Study: 14681344
Drug: YH1885 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH1885 200 mg single dose
Study: 14681344
Drug: YH1885 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH1885 300 mg single dose
Study: 14681344
Drug: YH1885 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH1885 150 mg multiple doses (once-daily for 7 days)
Study: 14681344
Drug: YH1885 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH1885 300 mg multiple doses (once-daily for 7 days)
Study: 30480487
Drug: Autologous Blood
Normalized name: Banked autologous blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous Blood Patch Injection (ABPI)
Study: 23721033
Drug: Occlusal appliance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occlusal appliance therapy
Study: 19040623
Drug: Lodenafil carbonate
Normalized name: Lodenafil carbonate
DrugBank: Lodenafil carbonate (DB11927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lodenafil carbonate 80 mg
Study: 19040623
Drug: Lodenafil carbonate
Normalized name: Lodenafil carbonate
DrugBank: Lodenafil carbonate (DB11927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lodenafil carbonate 40 mg
Study: 19040623
Drug: Lodenafil carbonate
Normalized name: Lodenafil carbonate
DrugBank: Lodenafil carbonate (DB11927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lodenafil carbonate 20 mg
Study: 16546471
Drug: Isoflavone intake
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone intake (75 mg of isoflavones conjugates per day)
Study: 31107300
Drug: Protease inhibitors
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitors
Study: 9578788
Drug: DTPw-HB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPw-HB vaccine
Study: 29630706
Drug: Narrative emphasizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative emphasizing systemic barriers to treatment
Study: 29630706
Drug: Narrative emphasizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative emphasizing successful treatment and recovery
Study: 26823137
Drug: High volume
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High volume IV fluid (20 mL/kg bolus + 1.5 × maintenance rate)
Study: 26823137
Drug: Low volume
Normalized name: CONNECTOR,LOW VOLUME,ENFIT MOOG INFINITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low volume IV fluid (10 mL/kg bolus + 1.25 × maintenance rate)
Study: 20106580
Drug: 35 mg
Normalized name: papain 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg of tartrazine dye
Study: 12600913
Drug: High-dose milrinone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose milrinone (75-microg/kg bolus followed by a 0.75-microg/kg per min infusion for 35 hours)
Study: 12600913
Drug: Low-dose milrinone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose milrinone (25-microg/kg bolus followed by a 0.25-microg/kg per min infusion for 35 hours)
Study: 12600913
Drug: High-dose milrinone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose milrinone